Key result
Hydroxychloroquine plus azithromycin is linked to ~12 ms QTc prolongation without fatal arrhythmias.
Why the study?
Hydroxychloroquine or chloroquine treatment for COVID-19 was associated with QT interval prolongation and arrhythmia risks, motivating evaluation of QTc interval and ventricular repolarization dispersion changes after administration with or without azithromycin.
Observational (n=130)
Single-blind
Yes
Answers are grounded in this paper and cite their sources.
Supports ECG monitoring with HCQ/CQ plus azithromycin; leaves open whether modest repolarization changes increase arrhythmia risk.
Background Hydroxychloroquine/chloroquine (HCQ/CQ) treatment for COVID‐19 was associated with QT interval prolongation and arrhythmia risks. This study aimed to investigate QTc interval and ventricular repolarization dispersion changes, as markers of arrhythmia risks, after HCQ/CQ administration with/without azithromycin (AZT) during COVID‐19 pandemic. Methods A prospective observational study was performed in two academic hospitals in Indonesia. Adult patients who received HCQ/CQ alone and HCQ/CQ + AZT concomitant treatments for COVID‐19 infection were enrolled. Baseline and post HCQ/CQ treatment electrocardiograms were obtained. Baseline and post HCQ/CQ treatment QT interval by Bazett (B‐QTc) and Fridericia (F‐QTc) formulas and ventricular repolarization dispersion indices by Tpeak‐Tend (Tp‐e) interval and Tpeak‐Tend/QT (Tp‐e/QT) ratio were calculated and analyzed. Results The study enrolled 55 (HCQ/CQ alone) and 77 subjects (HCQ/CQ + AZT concomitant). F‐QTc interval significantly lengthened in subjects with HCQ/CQ + AZT (mean difference 11.89 ms [P = .028]). The incidences of severe B‐QTc and F‐QTc lengthening were 13.1% and 12.3%, B‐QTc and F‐QTc prolongation were 25.4% and 12.3%, and severe B‐QTc and F‐QTc prolongation were 6.2% and 3.2%. Tp‐e interval lengthened significantly from baseline to posttreatment in HCQ/CQ alone and HCQ/CQ + AZT (mean difference 10.83 ms [P = .006] and 18.73 ms [P < .001], respectively). Tp‐e/QT ratio increased significantly from baseline to posttreatment in HCQ/CQ + AZT concomitant (mean difference 0.035 [P < .001]). No fatal arrhytmia occurred. Conclusions During COVID‐19 pandemic, HCQ/CQ + AZT concomitant treatment caused significant F‐QTc lengthening, significantly increased Tp‐e interval and increased Tp‐e/QT ratio. HCQ/CQ alone only caused significant increase of Tp‐e interval. Incidences of severe QTc lengthening and prolongation were low in both HCQ/CQ alone and HCQ/CQ + AZT concomitant.
No takes yet. Share an insight, caveat, or question.
Gumilang et al. (2021) conducted an observational in COVID-19 (n=130). Hydroxychloroquine/chloroquine with azithromycin (HCQ/CQ + AZT) vs. Baseline (pre-treatment) and HCQ/CQ alone was evaluated on Change in Fridericia QTc (F-QTc) interval from baseline to posttreatment in the HCQ/CQ + AZT group (MD 11.89 ms, 95% CI 1.27 to 22.53, p=0.028). Concomitant hydroxychloroquine/chloroquine and azithromycin significantly lengthened Fridericia QTc by 11.89 ms (P=0.028) and Tpeak-Tend by 18.73 ms (P<0.001) without fatal arrhythmias.
Synapse has enriched 10 related papers. Consider them for comparative context: